Machine Learning

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Syntax Data launches Saidee, an AI that builds custom portfolios using proprietary, traceable data, aiming to solve key compliance fears for financial advisors.

As Singapore mandates e-invoicing, Cygnet.One leverages its global platform to simplify complex digital tax compliance for multinational enterprises.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

Ad-tech giant Teads reports massive revenue growth post-merger, but a $352M impairment and restructuring signal deep integration challenges.

Following key acquisitions, the AI firm pivots to a vertically integrated defense powerhouse, forecasting explosive growth backed by a swelling order backlog.

With a new CEO known for scaling firms for acquisition, AI-native platform CYPHER Learning signals a major push for dominance in enterprise training.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

With $15M from top UAE families, TruDoc is scaling its 'hospital-at-home' model, signaling a major shift in how the GCC delivers critical care.

A Chinese firm's win at a top Korean battery expo signals a major shift in manufacturing tech, accelerating the path to cheaper, greener, solid-state batteries.

A Chinese firm's innovative probiotic packaging just won a top design award, solving a key industry problem and signaling a new era for 'Made in China'.

ST's new STM32C5 microcontroller series promises to bring high-end performance and robust security to billions of cost-sensitive smart devices.

A new global survey reveals the crushing mental burden of diabetes, sparking a call for AI-powered tools that promise to restore spontaneity and control.

Backed by Nobel-winning science and French state support, Pasqal's move to go public validates the commercial promise of deep quantum technology.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.

The staffing firm saw revenue fall 22% and posted a $95M net loss in 2025, now pivoting to its tech platform and cost cuts for a comeback.

The energy services firm surpassed analyst expectations with strong revenue growth and a key acquisition, but warns of a challenging year ahead.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

At PDAC 2026, Italy and Canada solidified a strategic partnership for critical minerals, powered by Italian technology and a new digital trade platform.

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.